Status:
NOT_YET_RECRUITING
Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy
Lead Sponsor:
Centre Antoine Lacassagne
Conditions:
Cerebrovascular Circulation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to ...
Eligibility Criteria
Inclusion
- Chronic stenosing cerebral vascular pathology (stenosis \> 70% on Doppler examination or angiography).
- Patient aged over 18 years.
- Patient who has voluntarily agreed to participate in the study and has signed the written informed consent.
- Patient affiliated with a social security system.
Exclusion
- Patient with stenosis less than 70% on Doppler examination or angiography.
- Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L).
- Patient with a contraindication to scintigraphy.
- Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®).
- Patient enrolled in another clinical study with a specified exclusion period.
- Minor patient.
- Patient unable to give informed consent.
- Vulnerable individuals
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06584747
Start Date
October 1 2024
End Date
October 1 2026
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Antoine Lacassagne
Nice, France, 06000